Topical Retinoids

Topical retinoid application may be an effective approach in early stage MF. They exert their effects through two basic types of nuclear receptors: the retinoic acid (RAR) and rexinoid (RXR) receptor family. No comparison of different retinoids has been evaluated. In a dose-escalating phase I/II trial of the RXR-specific retinoid bexarotene, 0.1-1.0%, the CR rate was 21%, with an overall response rate of 63%.28 Side effects were restricted to the application site and consisted of mild to moderate irritation, with erythema in 73% of the cases. Bexarotene 1% gel was approved by the Food and Drug Administration (FDA) as a therapy for stages IA through IIA MF.

0 0

Post a comment